Vol. 3 No. 6 (2026), Articles
Vol. 3 No. 6 (2026)

SEMIRISHNING JIGAR VA OSHQOZON-ICHAK KASALLIKLARI RIVOJLANISHIDAGI ROLI: PROFILAKTIKA VA VAZN NAZORATINING AHAMIYATI

Articles
Published 2026-09-08
Qurbonova Zarina Anvarovna
Samarqand Davlat Tibbiyot Universiteti talabasi
Abdipattayeva Kibriyo Abror qizi
Samarqand Davlat Tibbiyot Universiteti talabasi
Turaxonova Malika Muzaffar qizi
Samarqand Davlat Tibbiyot Universiteti talabasi
Shopulatova Dilnavo Erkin qizi
Samarqand Davlat Tibbiyot Universiteti talabasi
PDF

Keywords

semirish, visceral yog', insulin rezistentligi, jigar yog' bosishi kasalligi, NAFLD, NASH, o't-tosh kasalligi, gastroezofageal reflyuks kasalligi, kolorektal saraton, vazn nazorati.

Abstract

Semirish — dunyo bo'ylab tobora ortib borayotgan, ko'plab surunkali kasalliklarning rivojlanishida markaziy o'rin tutuvchi omillardan biri bo'lib, jigar va oshqozon-ichak tizimiga bevosita va bilvosita salbiy ta'sir ko'rsatadi. Ushbu maqolada semirishning gepatobiliar va gastrointestinal traktga ta'sir mexanizmlari — visceral yog' to'qimasining endokrin faolligi, adipokinlar disbalansi, insulin rezistentligi hamda surunkali past darajali yallig'lanish asosida tahlil qilingan. Semirishning jigar yog' bosishi kasalligi (NAFLD/MASLD), noalkogol steatogepatiti (NASH), o't-tosh kasalligi, gastroezofageal reflyuks kasalligi hamda kolorektal saraton rivojlanishidagi roli zamonaviy epidemiologik va klinik ma'lumotlar asosida yoritilgan. Maqolaning asosiy qismi ushbu kasalliklarning diagnostikasi, farqlash mezonlari hamda vazn nazorati va profilaktik chora-tadbirlarning gepatobiliar va gastrointestinal salomatlikka ta'sirini o'rganishga bag'ishlangan.

PDF

References

World Health Organization. Obesity and overweight. Fact sheet. Geneva: WHO; 2024.

2. Rinella M.E., Lazarus J.V., Ratziu V., et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature (MASLD). J Hepatol. 2023;79(6):1542-1556.

3. European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on NAFLD. J Hepatol. 2016;64(6):1388-1402.

4. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Feldman M., Friedman L.S., Brandt L.J. 11th ed. Elsevier; 2021.

5. Harrison's Principles of Internal Medicine. Jameson J.L., Fauci A.S., Kasper D.L., et al. 21st ed. McGraw-Hill; 2022.

6. Younossi Z.M., Koenig A.B., Abdelatif D., et al. Global epidemiology of NAFLD—metaanalysis. Hepatology. 2016;64(1):73-84.

7. Stinton L.M., Shaffer E.A. Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut Liver. 2012;6(2):172-187.

8. Hampel H., Abraham N.S., El-Serag H.B. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143(3):199-211.

9. Ma Y., Yang Y., Wang F., et al. Obesity and risk of colorectal cancer: a systematic review of prospective studies. PLoS One. 2013;8(1):e53916.

10. Islamov B.S., Karimova N.T. Semirish va gepatobiliar tizim kasalliklari. Toshkent: Tibbiyot; 2022.

11. Axmedov X.A. Gastroenterologiya asoslari. Toshkent; 2021.

12. Rustamova M.T., va boshq. O'zbekiston aholisida semirish tarqalishi va uning jigar-oshqozon-ichak trakti kasalliklariga ta'siri. Toshkent tibbiyot jurnali. 2022;2:38-46.